Drug Trial Radar · NCT03027284
A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer
Last checked: Nov 19, 2026Latest source record: May 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Feb 3, 2017
Primary completion
Jun 20, 2019
Study completion Mar 17, 2020
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Jan 23, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate tolerability of merestinib monotherapy or in combination with other anti-cancer agents in Japanese participants with advanced and/or metastatic cancer.
Conditions
- Advanced Cancer
- Metastatic Cancer
- Biliary Tract Carcinoma
- Cholangiocarcinoma
- Gall Bladder Carcinoma
- Solid Tumor
- Non-Hodgkin's Lymphoma
Interventions
MerestinibDrug
Administered orally
CisplatinDrug
Administered IV
GemcitabineDrug
Administered IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Merestinib Dose-Limiting Toxicities (DLTs)Time frame: Cycle 1 (Part A = 28 Days or Part B = 21 Days)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Chiba, Japan
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.